Business Context and Reporting Period
This Form 8-K filing by Zura Bio Ltd (ZURA) was submitted on June 22, 2023, with the report dated October 2, 2023. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: On May 31, 2023, the Board of Directors increased its size from seven to nine directors.
- New Appointment: On June 22, 2023, Parvinder Thiara was appointed to fill a vacancy on the Board. He will serve until the next annual meeting of stockholders or until his successor is elected.
Management Commentary and Background
Management highlighted Mr. Thiara's qualifications, noting his role as Chief Investment Officer and founder of Athanor Capital, a New York-based hedge fund manager. He also serves on the board of Tourmaline Bio and previously held senior roles at D.E. Shaw & Co. The Company cited his medical and scientific background combined with life sciences investment experience as key reasons for his appointment. No family relationships or material transactions involving Mr. Thiara in the past two years were disclosed.
Investor Verification Checklist
- Verify the effective date of Parvinder Thiara's board appointment (June 22, 2023).
- Confirm the total number of directors on the Board is now nine.
- Review Mr. Thiara's existing board commitments, specifically his role at Tourmaline Bio, for potential conflicts of interest.
- Check subsequent filings for the date of the next annual meeting of stockholders to determine the end of Mr. Thiara's current term.